Monday , December 18 2017
Home / David L. Joffe, BSPharm, CDE, FACA (page 12)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA

(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Dec. 15, 2016

Recently the ADA and the AHA came together to adjust the guidelines in diabetes patients with cardiovascular problems. They have agreed that managing the cardiovascular problems should be the guiding light in overall patient care, and worrying about A1c levels is of less importance. This is especially true in older patients. …

Read More »

Dec. 13, 2016

A few years ago Dr. Steven Nissen turned the diabetes world upside down when he went on a crusade to get TZD’s off the market due to cardiovascular risk. One of the results of his efforts was the FDA’s requirement that all new diabetes drugs would have extensive cardiovascular testing, …

Read More »

Dec. 10, 2016

Over the years Steve and I have reviewed many PowerPoint presentations on diabetes, and we have published quite a few of these ourselves. Whenever the presentation explained how type 2 diabetes developed, there was always a slide showing increased insulin resistance and decreased insulin production. Wherever these 2 lines crossed, …

Read More »

Dec. 8, 2016

It has been 10 years since Sitagliptin was approved by the FDA. When it was first approved there was a lot of pushback from prescribers to trying a new class, as the last class, the TZDs, had suffered through the problems with Rezulin and the cardiovascular problems associated with Actos …

Read More »

Dec. 6, 2016

As we approach the holiday season a lot of patients will bring you gifts, and many of them will be handmade creations, including some of the gaudiest sweaters known to mankind. Some people are good enough to design these creations as they go along, but most people have to use …

Read More »

Dec. 3, 2016

When I first met Steve Freed 22 years ago, it was because of my desire to get pharmacists involved with a nutritional multilevel marketing company. Although I was a pharmacist, I did not really have an interest or passion for diabetes like I do now. The company I was involved …

Read More »

Nov. 29, 2016

Each and every week, we try to bring you the best in diabetes care in our clinical newsletter. However, no matter how much education we give a patient or how great the new drugs are, if a patient can’t afford the medicines they need then they are doomed to failure. …

Read More »

Nov. 26, 2016

Happy Thanksgiving from all of us here at Diabetes In Control! Many of us are too old to remember how hard tests were when we were in school. In addition, the way learning works now there is always a good chance you can Google the answer. So, the question that …

Read More »

Nov. 22, 2016

On Monday, the FDA gave approval to NovoNordisk’s new combination product, Xultophy. This is a combination of the super long-acting insulin degludec and the once daily GLP-1 agonist Liraglutide. The fixed dose combination is given in one to 50 dosing steps to maximize to glycemic control. The super long-acting insulin …

Read More »

Nov. 19, 2016

Recently I got to spend some time with the director of a kidney / liver transplant center in Largo, Fl. While I was touring the facility she was telling me about how they select candidates for kidney transplant, and the problems that keep people from being selected. We also talked …

Read More »